Baxter International said it agreed to acquire Cheetah Medical, the developer of a noninvasive fluid management monitoring system called the Starling SV for up to $230 million. The device’s sensor pads are applied to the chest, enabling clinicians to assess heart function and fluid responsiveness to determine the amount needed for the individual patient to maintain optimal organ and tissue perfusion. The technology is designed for use in critical care, operating room and emergency department settings. Baxter agreed to pay $190 million in cash for Cheetah, plus an additional $40 million to be paid upon achievement of clinical and commercial milestones.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
bacteria
binx health
Biosimilar
Blood Filter
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
colorectal cancer
Diagnostics
Digital Health
Drug Discovery
ExThera Medical
FDA
FDA approval
funding
fundraising
glycosylation
Halodoc
HIV
Innovation
Licensing
M&A
medical device
medtech
microbial
microbial DNA
microbial RNA
microbiome
Neuro
Novartis
pharma
Pharming
Prescient Metabiomics
robots
software
Therapeutics
Therapy
USA
VIrology
women health